医学
前列腺癌
外照射放疗
泌尿科
经尿道前列腺电切术
前列腺
切除术
下尿路症状
泌尿系统
外束辐射
放射科
放射治疗
上尿路
前列腺切除术
肿瘤科
内科学
并发症
外科
作者
Casper Vrij,Harman Maxim Bruins,Kevin L. J. Rademakers,Tom J.N. Hermans,Elisabeth J.M. Driessen,Chiara Coleman,Evert van Limbergen,Franchette van den Berkmortel,Mathie Leers,John P.F.A. Heesakkers
出处
期刊:The Journal of Urology
[Lippincott Williams & Wilkins]
日期:2026-11-10
卷期号:: 101097JU0000000000005388-101097JU0000000000005388
标识
DOI:10.1097/ju.0000000000005388
摘要
PURPOSE: To describe the safety and efficacy of planned transurethral resection of the prostate (TURP) prior to external beam radiotherapy (EBRT) in patients with prostate cancer and lower urinary tract symptoms. MATERIALS AND METHODS: Patients who underwent TURP ≤9 months before EBRT between March 2015 and March 2025 were included in this multicentre retrospective cohort. Urinary adverse events (UAE) were graded using Common Terminology Criteria for Adverse Events version 6. Cumulative incidence of grade ≥2 and ≥3 UAE was estimated with the Aalen-Johansen method with dead as a competing event, and associations with UAE after EBRT were explored with multivariable Cox regression. International Prostate Symptom Scores (IPSS) were analysed with linear mixed effects models. RESULTS: A total of 200 patients were included. Median follow-up after EBRT was 30 months among patients without a grade ≥3 UAE. The cumulative incidence at 36 months after EBRT was 53% (95% CI 46 - 61) for grade ≥2 and 14% (95% CI 9.1 - 20) for grade ≥3 UAE. A longer TURP-EBRT interval was associated with grade ≥2 UAE (hazard ratio 1.18 per month, 95% CI 1.03 - 1.36), likely reflecting confounding by indication. A larger clinical target prostate volume was associated with a lower risk of grade ≥3 UAE (HR 0.95 per mL, 95% CI 0.92 - 0.99). The estimated mean IPSS decreased from 19.8 before to 11.1 after TURP and remained close to or below this level after EBRT. CONCLUSIONS: Pre-EBRT TURP is feasible, with manageable but clinically relevant urinary toxicity. Symptom improvement is maintained after EBRT. These findings support its use as a de-obstructive strategy in patients with prostate cancer and lower urinary tract symptoms requiring EBRT.
科研通智能强力驱动
Strongly Powered by AbleSci AI